FDA approves IBS drug for children, Linzess, to treat pediatric IBS-C in patients ages 7 and older with proven safety and efficacy.
The malignant pediatric brain tumor medulloblastoma is driven by proteins deep within the cancer cells, for which there are often no effective drugs available. Researchers at Uppsala University have ...
A new study conducted by University Hospitals Connor Whole Health highlights the impact of pediatric integrative medicine ...
Dispensing errors for pediatric orders are particularly perilous and can be partially explained by the relative lack of education pharmacists receive regarding medications and children. Pharmacists ...
The U.S. Food and Drug Administration (FDA) has granted rare pediatric drug designation for iopofosine-131 in inoperable relapsed or refractory pediatric high-grade glioma (pHGG), according to a news ...
PolyActiva and RareSight collaborate to create innovative therapies for rare pediatric retinal diseases, aiming to transform ...
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival and Overall Survival ...
New research from the University of Alabama at Birmingham suggests that young patients with acute lymphocytic leukemia, or ALL — the most common type of pediatric cancer — and their parents are likely ...
Cost-Effectiveness of Oral Levofloxacin Versus Amoxicillin-Clavulanate/Ciprofloxacin for Outpatient Management of Low-Risk Febrile Neutropenia in Children With Cancer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback